Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd

CAR-T Digest - August 2020

18 March 2026: Aptamer Group initiated Optimer radiopharmaceutical programme with Radiopharmium Ltd

Aptamer Group plc has officially entered the fast-growing radiopharmaceutical space, launching a targeted programme built around its Optimer platform in collaboration with Radiopharmium Ltd
This move is strategically timed, as the radiopharmaceutical market continues to expand rapidly, prompting Aptamer to identify three high-value therapeutic targets and begin building a proprietary pipeline aimed at addressing key clinical needs
At the heart of the programme lies the Optimer technology, designed to overcome longstanding limitations of radioligand therapies particularly instability caused by radioactive payloads that can degrade targeting molecules and complicate storage and delivery
Early data already signals differentiation, with Optimer-based radioligands showing significantly improved stability compared to conventional peptide approaches when tested with isotopes like Gallium-68 and Lutetium-177 potentially enabling longer shelf life and more efficient clinical use
With development now underway, the programme is expected to expand Aptamer’s radiotherapy pipeline to four assets, progressing through preclinical validation and targeting in vivo data by the end of 2026 marking an important step toward next-generation targeted radiotherapies